[1] Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clin Infect Dis. 2009, 49 (3):325-327.
[2] Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, Am J Health-Syst Pharm, 2009, 66 (1):82-98.
[3] Vancomycin clinical application Chinese expert consensus, Chinese Journal of New Drugs and Clinical Medicine,2011, 30 (8): 561-573. [In Chinese]
[4] Vancomycin clinical application dose Chinese expert consensus, Chinese Journal of Infectious Diseases,2012, 30 (11): 641-646. [In Chinese]
[5] Stuart L. Goldstein. Nephrotoxicities. F1000Res. 2017, 6 (55): doi: 10.12688.
[6] John A. Bosso, Jean Nappi, Celeste Rudisill, et al. Relationship between vancomycin trough concentration and nephrotoxicity: a prospective multi-center trial. Antimicrob Agents Chemouther, 2011, 55 (12): 5475-5479.
[7] Mergenhagen KA, Borton AR. Vancomycin nephrotoxicity: a review. J Pharm Pract. 2014, 27 (6): 545-553.
[8] Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clin Pharmacol Ther, 2017, 102 (3):459-469.
[9] Pan K, Ma L, Xiang Q, et al. Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China. PLoS One. 2017, 12 (4): e0175688
[10] Jeffres MN. The Whole Price of Vancomycin: Toxicities, Troughs, and Time. J Drugs. 2017 Jul; 77 (11): 1143-1154.
[11] Levine DP. Vancomycin: a history. Clin Infect Dis. 2006, 42: S5-12.
[12] Hopl, Lopy, Chowkh, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infection. 2010, 60:140-145.
[13] Gao Feifei, Chen Chaoyang, Sheng Xiaoyan, et al. Evaluation of the population pharmacokinetic models of vancomycin in geriatric patients. Clinical Medication Journal.2017, 15:30-34. [in Chinese].
[14] Levey AS, Stevens LA, Schmid CH, et al, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009, 150 (9): 604612.
[15] Lin WW, Wu W, Jiao Z, et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualized dosage regimens[J]. European Journal of Clinical Pharmacology, 2015, 72 (01): 29-37.
[16] Zhou Y, Gao F, Chen C, et al. Development of a Population Pharmacokinetic Model of Vancomycin and its Application in Chinese Geriatric Patients with Pulmonary Infections. Eur J Drug Metab Pharmacokinet. 2019, 44 (3):361-370.
[17] Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012, 2: 1–138.
[18] Leu WJ, Liu YC, Wang HW, et al. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis. 2012, 16(11): e804-10.
[19] Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey. The Lancet. 2015, 386: 1465–1471.
[20] Ricci Z, Ronco C. Timing, dose and mode of dialysis in acute kidney injury. Curr Opin Crit Care. 2011,17(6):556-61.
[21] Rybak M, B. Lomaestr, JC. Rotschafer, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009, 66:82-98.
[22] Michael J, Ben M, John C, et al. Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Vancomycin Therapeutic Guidelines. 2009, 49 :325-327.
[23] Huang ZY, Xiao YH, Zhang J, et al. Chinese expert consensus on clinical application of vancomycin (2011). Chin J New Drugs Clin Rem. 2011, 30: 561-573. [in Chinese].
[24] Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin[J]. Clin Pharmacol Ther, 2017, 102 (03): 459-469.
[25] Smith AP, Millares-Sipin CA, James M. Impact of a Pharmacist-Initiated Vancomycin Monitoring Program. Consult Pharm. 2016, 31(9):505-10.
[26] Zhou Y, Liu X, Ma L, Chen C, Yang T, Zhang X, et al. Status analysis of clinical application and acute renal injury monitoring of vancomycin in some areas of China. Chin J Clin Pharmacol. 2019, 35 (12): 82-86.
[27] Wang Min, Liu Hang, Jin Lu, et al. Research on the Therapeutic Drug Monitoring and Nephrotoxicity of Vancomycin in Elderly Patients. Pharmaceutical and Clinical Research. 2019, 27 (2): 98-100. [In Chinese]
[28] PAN Kun-ming,MA Ling-yun,XIANG Qian, et al. Current situation survey and risk factors of vancomycin-associated acute kidney injury in older patients. Chinese Journal of New Drugs. 2017, 15: 1848-1856 [In Chiese]
[29] Sun L, Tian S, Ma L, Zhao L, Zhou Y, Cui Y, et al.: Comprehensive assessment system of vancomycins’ rational use. Chin J Clin Pharmacol. 30: 143-145, 2014
[30] Smith AP, Millares-Sipin CA, James M, et al. Impact of a Pharmacist-Initiated Vancomycin Monitoring Program. Consult Pharm. 2016 Sep;31(9):505-10.
[31] Marquis KA, DeGrado JR, Labonville S, et al. Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center. Ann Pharmacother. 2015 Sep;49 (9):1009-14.
[32] Deng C, Liu T, Zhou T, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis[J]. Int J Clin Pharmacol Ther, 2013, 51(05): 407-15.
[33] LI Fan, LIU Xiaoling. Study on Application of JPKD Population Pharmacokinetics Software in Individualized Administration of Vancomycin. Anti Ifect Pharm. 2019, 16 (2): 195-199. [In Chinese]
[34] Liu Liu, Li Yuanyuan. Practice of Individual Vancomycin Administration Based on Population Pharmacokinetic Model. China Pharmacist. 2019, 22 (9): 1663-1666. [In Chinese]
[35] Leu WJ, Liu YC, Wang HW, et al. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis. 2012, 16: e804–810.